StockData
Transcode Therapeutics, Inc. logo

Transcode Therapeutics, Inc. (RNAZ) stock

RNAZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026Score 5/30
$1.32−0.07 (-5.06%)

Close on Nov 13, 2026Market cap $1.34MP/E –Yield –

Transcode Therapeutics cash

Cash and short-term investments held at the end of each period.

Transcode Therapeutics's cash was $8.38M at Jun 30, 2026. For fiscal 2025 it was $17.81M, up 206.5% from the year before. The highest annual figure on record is $20.83M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$17.81M+206.5%
FY2024Dec 31, 2024$5.81M+110.0%
FY2023Dec 31, 2023$2.77M-44.3%
FY2022Dec 31, 2022$4.97M-76.1%
FY2021Dec 31, 2021$20.83M+2415.2%
FY2020Dec 31, 2020$828.02K+305.0%
FY2019Dec 31, 2019$204.47K–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$8.38M+13.7%
Q1 FY2026Mar 31, 2026$12.84M+10.9%
Q4 FY2025Dec 31, 2025$17.81M+206.5%
Q3 FY2025Sep 30, 2025$2.84M+51.2%
Q2 FY2025Jun 30, 2025$7.37M+119.8%
Q1 FY2025Mar 31, 2025$11.57M+135.4%
Q4 FY2024Dec 31, 2024$5.81M+110.0%
Q3 FY2024Sep 30, 2024$1.88M-74.8%
Q2 FY2024Jun 30, 2024$3.35M-6.1%
Q1 FY2024Mar 31, 2024$4.91M+202.8%
Q4 FY2023Dec 31, 2023$2.77M-44.3%
Q3 FY2023Sep 30, 2023$7.45M-15.2%
Q2 FY2023Jun 30, 2023$3.57M-73.4%
Q1 FY2023Mar 31, 2023$1.62M-90.4%
Q4 FY2022Dec 31, 2022$4.97M-76.1%
Q3 FY2022Sep 30, 2022$8.79M-60.9%
Q2 FY2022Jun 30, 2022$13.44M+16789.4%
Q1 FY2022Mar 31, 2022$16.85M+16929.4%
Q4 FY2021Dec 31, 2021$20.83M+2415.2%
Q3 FY2021Sep 30, 2021$22.50M+1953.0%
Q2 FY2021Jun 30, 2021$79.57K-93.8%
Q1 FY2021Mar 31, 2021$98.96K-51.6%
Q4 FY2020Dec 31, 2020$828.02K–
Q3 FY2020Sep 30, 2020$1.10M–
Q2 FY2020Jun 30, 2020$1.29M–
Q4 FY2019Dec 31, 2019$204.47K–

More Transcode Therapeutics figures

See a number that looks wrong?